联合健康净利大增背后有隐忧！国内健康险如何借鉴？_老虎社区_美港股上老虎

联合健康净利大增背后有隐忧！国内健康险如何借鉴？

市场资讯07-24

原标题：中保观察 | 联合健康净利大增背后有隐忧！国内健康险如何借鉴？　　来源：中保新知　　7月16日，美国最大的商业医疗保险公司联合健康集团（UnitedHealth Group）交出了一份让华尔街意外的成绩单：第二季度调整后每股收益6.38美元，远超分析师此前4.86—4.91美元区间的预期，公司股价在财报公布后一度飙升逾6%。这份“惊喜”背后，藏着一道美国医疗保险行业正在集体面对的选择题...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohunote.com/m/news/2653082495?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-24 20:35","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2653082495","market":"hk","top_or_hot":-1,"title":"联合健康净利大增背后有隐忧！国内健康险如何借鉴？","media":"市场资讯","content":"<div>\n<p>原标题：中保观察 | 联合健康净利大增背后有隐忧！国内健康险如何借鉴？\n　　来源：中保新知\n　　7月16日，美国最大的商业医疗保险公司联合健康集团（UnitedHealth Group）交出了一份让华尔街意外的成绩单：第二季度调整后每股收益6.38美元，远超分析师此前4.86—4.91美元区间的预期，公司股价在财报公布后一度飙升逾6%。这份“惊喜”背后，藏着一道美国医疗保险行业正在集体面对的选择题...</p>\n\n<a href=\"https://finance.sina.com.cn/wm/2026-07-24/doc-iniixfyi1622186.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>联合健康净利大增背后有隐忧！国内健康险如何借鉴？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n联合健康净利大增背后有隐忧！国内健康险如何借鉴？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-24 20:35 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/wm/2026-07-24/doc-iniixfyi1622186.shtml><strong>市场资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>原标题：中保观察 | 联合健康净利大增背后有隐忧！国内健康险如何借鉴？\n　　来源：中保新知\n　　7月16日，美国最大的商业医疗保险公司联合健康集团（UnitedHealth Group）交出了一份让华尔街意外的成绩单：第二季度调整后每股收益6.38美元，远超分析师此前4.86—4.91美元区间的预期，公司股价在财报公布后一度飙升逾6%。这份“惊喜”背后，藏着一道美国医疗保险行业正在集体面对的选择题...</p>\n\n<a href=\"https://finance.sina.com.cn/wm/2026-07-24/doc-iniixfyi1622186.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014914.USD","symbol_name":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","start_time":0,"source_url":"https://finance.sina.com.cn/wm/2026-07-24/doc-iniixfyi1622186.shtml","article_id":"2653082495","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653082495","pubTimestamp":1784896500,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　7月16日，美国最大的商业医疗保险公司联合健康集团交出了一份让华尔街意外的成绩单：第二季度调整后每股收益6.38美元，远超分析师此前4.86—4.91美元区间的预期，公司股价在财报公布后一度飙升逾6%。　　联合健康二季度营收1120.3亿美元，同比、环比均基本持平；净利润54.8亿美元，合每股6.04美元，较2025年同期的3.41亿美元、每股3.74美元大幅提升。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","XLV":"健康照护类股ETF-SPDR","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","BK4534":"瑞士信贷持仓","LU0149725797.USD":"汇丰美国股市经济规模基金","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0079474960.USD":"联博美国增长基金A","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","IYH":"iShares U.S. Healthcare ETF","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","MHIP":"Milliman Healthcare Inflation Plus ETF","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","TRUH":"VanEck Healthcare TruSector ETF","LU0557290698.USD":"施罗德环球可持续增长基金","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","HRTS":"Tema Heart & Health ETF","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","VHT":"Vanguard Health Care ETF","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","UNHG":"2倍做多UNH ETF-Leverage Shares","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0342679015.USD":"ALLIANZ GLOBAL EQUITY UNCONSTRAINED \"AT\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","UNHU":"Direxion Daily UNH Bull 2X ETF","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","UNHW":"Roundhill UNH WeeklyPay ETF","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","BK4588":"碎股","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4154":"管理型保健护理","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","TMED":"T. Rowe Price Health Care ETF","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","BK4566":"资本集团","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","FHLC":"Fidelity MSCI Health Care Index","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0861579265.USD":"联博低波幅策略股票基金A","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","IHF":"iShares Dow Jones U.S. Health Ca","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0143551892.USD":"T ROWE PRICE GLOBAL FOCUSED GROWTH EQUITY \"A\" (USD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2462591277.SGD":"TRP GLOBAL FOCUSED GROWTH EQUITY \"AN\" (SGDHDG) ACC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2954938101.SGD":"T ROWE PRICE GLOBAL FOCUSED GROWTH EQUITY \"A8P\" (SGD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","IXJ":"全球医疗业ETF-iShares","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU2999663052.SGD":"T ROWE PRICE GLOBAL FOCUSED GROWTH EQUITY \"A4P\" (SGD) INC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2279689827.SGD":"JPMorgan Investment Funds - Global Income Sustainable A (mth) SGD-H","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","UNH":"联合健康","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","RXL":"ProShares Ultra Health Care","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","GDOC":"Goldman Sachs Future Health Care Equity ETF","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC"},"translate_title":"There are hidden worries behind the huge increase in United Health's net profit! How to learn from domestic health insurance?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IHF":0.6,"UNH":1.95,"IYH":0.6,"FHLC":0.6,"RXL":0.6,"HRTS":0.6,"UNHG":0.6,"UNHW":0.6,"VHT":0.6,"GDOC":0.6,"TMED":0.6,"JDOC":0.6,"XLV":0.6,"TRUH":0.6,"MHIP":0.6,"UNHU":0.6,"IXJ":0.6},"content_text":"原标题：中保观察 | 联合健康净利大增背后有隐忧！国内健康险如何借鉴？\n　　来源：中保新知\n　　7月16日，美国最大的商业医疗保险公司联合健康集团（UnitedHealth Group）交出了一份让华尔街意外的成绩单：第二季度调整后每股收益6.38美元，远超分析师此前4.86—4.91美元区间的预期，公司股价在财报公布后一度飙升逾6%。这份“惊喜”背后，藏着一道美国医疗保险行业正在集体面对的选择题——用什么代价换取利润修复。\n　　联合健康二季度营收1120.3亿美元（约合人民币7618亿元），同比、环比均基本持平；净利润54.8亿美元，合每股6.04美元，较2025年同期的3.41亿美元、每股3.74美元大幅提升。公司同时将2026年全年调整后每股收益指引上调至19.5—20美元，高于此前“高于18.25美元”的预期。这是联合健康今年内第二次上调全年指引——今年4月公司曾在一季度财报超预期后，将全年指引从“高于17.75美元”上调至“高于18.25美元”。\n　　新近发布的《2026年安联全球保险业发展报告》指出， 2025年，全球健康险市场增长12.3%，创2014年以来最高增速，成为保险业最具活力的业务领域。在该领域中，美国市场占全球健康险保费的70%以上，北美健康险市场增速达14.9%。在亚洲，几乎所有市场健康险深度仍不足1%，长期增长潜力巨大。\n　　PART\n　　01\n　　成本管控与AI投入\n　　撑起利润修复的两大支柱\n　　联合健康首席执行官Stephen Hemsley在财报声明中将这份成绩归功于公司“简化运营方式、改善患者与医疗提供方的可及性与就医体验，并运用现代科技创造实际改善”的持续努力。\n　　具体到数字上，联合健康医疗成本率（medical care ratio）从2025年同期的89.4%改善至86.7%，公司同时将全年医疗成本率指引收窄至88.1%±25个基点，低于此前88.8%±50个基点的区间——这意味着联合健康为每一美元保费支付的医疗理赔成本比例正在下降。\n　　旗下健康服务部门Optum二季度营收657亿美元，营业利润40亿美元，营业利润率同比提升160个基点，季度内服务用户超过1.2亿人。联合健康保险公司（UnitedHealthcare）保险业务本身营业利润率也从2025年同期的2.4%提升至4.6%。首席财务官Wayne DeVeydt在财报电话会上强调，“这份财报质量非常扎实”，并表示19.50—20.00美元的指引区间是投资者可以使用的合理基准，公司甚至有能力做得更好。\n　　支撑这份成本管控成绩单的，还有一笔持续加码的技术投入：联合健康2026年计划在人工智能相关技术上投入近15亿美元，2027年预计维持相近规模。目前公司已经在业务各条线落地超过1000个AI应用场景，聘用了超过2000名AI工程师。Optum正持续向医院及其他医疗服务提供方推广AI产品，包括多支付方理赔解决方案与手术室排期预测分析工具。\n　　PART\n　　02\n　　数字背后的隐忧\n　　缩规模换利润\n　　“对整个系统而言不是好事”\n　　然而，这份亮眼财报的另一面，是一道并不轻松的权衡。二季度，联合健康服务人数为4850万人，较上一季度减少52.5万人。DeVeydt将会员流失主要归因于医疗成本上涨带来的保费可负担性压力，并预计公司全年将净流失约50万名ACA医疗保险交易所会员，以及110万名Medicare Advantage（联邦医保优势计划）会员。\n　　这并非年内首次下调会员预期。今年1月，联合健康在2025年全年财报中就曾预计，2026年商业保险、Medicare Advantage与Medicaid三条业务线合计会员数将减少230万至280万人，其中ACA交易所业务缩水规模超过50万人。UnitedHealthcare商业保险业务首席执行官Dan Kueter彼时坦言，公司在ACA交易所市场经营逾10年，这项业务“从未成为利润的重要贡献来源”。\n　　在4月举行的一季度财报会议上，联合健康进一步将Medicare Advantage会员流失预期从此前的100万人上调至130万—140万人，首席执行官Tim Noel将其定性为一次“审慎的、主动的”提价重定价策略，而非单纯为保住规模而被动应战。\n　　值得注意的是，联合健康整体营收之所以能在会员流失的情况下保持稳定，很大程度上依靠了提价——保费涨幅足以抵消流失的会员数量。但DeVeydt也直言不讳地指出了这种做法的局限：“用提价来抵消会员流失，这对整个医疗系统的长期健康而言不是一件好事。”\n　　这句话在某种程度上道出了美国商业医疗保险行业当下的普遍处境：在医疗成本持续攀升的背景下，保险公司要么继续为保住规模而承受利润压力，要么主动收缩承保范围、用价格换利润——而后者最终转嫁的，是消费者不断上涨的保费负担与保障范围的收窄。\n　　PART\n　　03\n　　中美对照\n　　一边“减量提价护利润”\n　　一边“短期承压长期看好”\n　　将视线转回国内市场，中国商业健康险行业正面临着性质不同、但同样棘手的增长焦虑。\n　　根据金融监管总局披露的数据，2025年国内商业健康险保费收入为9973亿元，同比增速仅2.04%，显著低于保险业整体7.4%的增速水平；今年前5个月，国内商业健康险保费收入为5521亿元，同比增速小幅回升至3.9%，其中人身险公司健康险保费3877亿元，增速近乎停滞，财产险公司健康险保费1644亿元，同比增长14.5%，行业增长动能正逐步由传统人身险机构向财险渠道转移。\n　　《2026年安联全球保险业发展报告》指出，与许多全球市场将健康险视作小众业务不同，健康险在中国是重要的保险品类，市场结构持续优化，保障功能日益凸显。受益于人口老龄化加速、医疗成本攀升、公共医疗体系承压等因素，中国健康险市场的长期增长潜力巨大。\n　　报告预测，未来十年中国健康险市场预计以8.1%的年均增长率领跑全球，成为最具活力的保险业务领域。这一增长主要受益于人口老龄化带来医疗健康需求持续扩容、公共医疗体系承压推动私人保障需求上升、居民健康意识觉醒和支付能力提升。随着“健康中国2030”战略的深入推进，中国健康险市场将迎来更大的发展机遇。\n　　联合健康用一份“减量增效”的财报告诉市场，短期利润修复是可以实现的，但代价是会员规模缩水与保费持续上涨，其CFO自己也承认这条路径“对系统长期健康不是好事”。\n　　在中保新知看来，中国商业健康险行业眼下还没有走到“要不要减量”这一步，真正的考验在于怎样从“粗放规模扩张”向“高质量精细化”转型，如何将行业增长引擎从“重疾险单轮驱动”向“医疗险主导、多险种协同”切换，并深度融入“医—药—险”大健康生态。\n　　各方的焦虑看似方向不同，但都指向同一个行业共识：健康险行业仅靠传统的承保+理赔模式，已经越来越难以独立支撑长期稳健的增长，技术投入正在成为几乎所有主要市场健康险公司共同押注的破局变量。\n　　国内头部险企已率先落地全链条AI医疗布局。近期，中国平安首次正式发布面向肿瘤等重疾患者的“专病AI产品矩阵”，包括专病预测、专病保险和北大医疗AI专病管家三类产品及服务。其中，专病预测识别风险，及早发现高危人群；专病保险承接风险，服务慢病、癌症等高风险人群；北大医疗AI专病管家提供肿瘤全病程管理，连接医生、医院和康复资源，为重疾客户提供连续服务，共同打通疾病风险发现、保险保障和专业医疗服务。\n　　在日常健康管理方面，旗下平安好医生宣布全新升级的“平安智享家医”服务已覆盖9000万月活用户。“平安智享家医”创新采用“AI+真人医生”双服务模式。一方面，凭借AI秒级响应可以高效处理问诊分流、用药提醒、体检报告解读等高频需求。另一方面，针对复杂病症问诊、慢病长期管控、在线处方开具等专业医疗需求，平台同步接入真人医生深度参与诊疗决策。目前，该服务已突破常识性问答的能力局限，实质性切入临床诊疗辅助环节。\n　　AI是中美两大市场不约而同选中的解法，但底层目标截然不同：美国企业依托技术压缩运营成本，对冲保费端的结构性压力；国内险企以医疗大模型、全流程AI服务补齐健康管理短板，配合制度建设拓宽保障边界。例如，今年4月，“平安医疗大模型3.5”在国际权威医疗AI评测平台HealthBench Hard取得57.27分，超越OpenAI等国际领先模型，位列全球第一。\n　　放眼长远，健康险的价值锚点终将脱离简单承保利差。对国内健康险而言，海外巨头的困境提供关键警示：单纯依靠涨价、收缩客群的盈利模式不具备可持续性。立足本土保障需求，持续以科技打通预防、诊疗、理赔、康养全链路，守住普惠属性的同时缓释长期风险，才是中国商业健康险走出独立发展路径的核心落脚点。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：秦艺","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}